Ligand Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of XOMA Royalty will double the portfolio size, add seven commercial royalties, and over 100 development-stage programs, driving immediate and long-term earnings growth. The all-cash deal is expected to be accretive from 2026, with significant synergies and no shareholder dilution.
Fiscal Year 2025
-
Delivered record 2025 results with 48% royalty revenue growth and 42% adjusted EPS increase, driven by strong commercial launches and portfolio expansion. 2026 guidance projects continued double-digit growth, supported by a robust late-stage pipeline and over $1B in deployable capital.
-
Management outlined a strategy focused on diversified royalty investing, driving strong financial growth and raising five-year royalty CAGR guidance to 23%. Key assets like Filspari, Ohtuvayre, and ZELSUVMI are fueling revenue, while the team and capital base have scaled to support more complex, high-return deals.
-
A diversified royalty aggregator leverages a lean, expert team to invest in over 100 biopharma assets, focusing on high-margin, low-risk cash flows. Recent financials show strong growth, with updated 2024 guidance and a robust five-year outlook driven by new product launches and portfolio expansion.
-
Q3 2025 saw record revenue and EPS growth, driven by strong royalty assets and a $53M gain from the Pelthos transaction. Full-year guidance was raised, with robust cash reserves and a $460M convertible note supporting an active investment pipeline.
-
A royalty aggregator with a diversified, high-margin portfolio, strong financial position, and scalable technology platforms is driving growth through strategic investments in late-stage and commercial biopharma assets. Recent product launches and acquisitions, including Ohtuvayre and FILSPARI, are boosting revenue and long-term outlook.
-
Q2 2025 saw 15% revenue growth and a 57% surge in royalty revenue, prompting raised full-year guidance for both revenue and EPS. Portfolio highlights include strong launches for Ohtuvayre and ZELSUVMI, a $40M investment in Orchestra BioMed, and a robust late-stage pipeline.
-
Revenue grew 46% year-over-year in Q1 2025, driven by strong royalty contributions from key assets and strategic investments. The company reaffirmed 2025 guidance and expects long-term royalty revenue CAGR of at least 22%, supported by a robust, diversified portfolio.
Fiscal Year 2024
-
2024 saw robust revenue and royalty growth, driven by new product launches and portfolio expansion. Strong cash position and disciplined capital allocation support a 22%+ CAGR outlook for royalties through 2029, with FILSPARI, Ohtuvayre, and Capvaxive as key growth drivers.
-
Significant restructuring and portfolio expansion have driven strong financial growth, with 2025 guidance projecting 17% revenue and 30% royalty growth. Key assets like QARZIBA, Ohtuvayre, FILSPARI, and ZELSUVMI underpin a >20% long-term CAGR outlook, supported by a robust pipeline and $350 million in available capital.
-
Q3 2024 saw 58% revenue growth and an 80% increase in adjusted EPS, driven by strong royalty revenue and new product launches. Guidance for 2024 was raised, with robust long-term growth expected from a diversified portfolio and disciplined capital deployment.
-
Q2 2024 revenue rose 58% year-over-year, driven by new product approvals and milestone payments, with royalty revenue up 11%. 2024 guidance was reaffirmed, and the portfolio expanded with key acquisitions and product launches, supporting strong long-term growth targets.